Aminov Erez 4

What Happened

• Erez Aminov, CEO of MIRA Pharmaceuticals (MIRA), was awarded 83,500 restricted stock units (RSUs) on March 30, 2026. The Form 4 shows an acquisition at $0.00 because RSUs are a derivative grant (not an open-market purchase). Per the filing, all RSUs were issued and vested on the grant date.

Key Details

• Transaction date and price: 2026-03-30; 83,500 RSUs @ $0.00 (derivative award).
• Footnotes: F1 — each RSU converts to one share of common stock; F2 — the RSUs were issued under the company plan and fully vested on the grant date.
• Shares owned after transaction: not specified in the provided filing summary.
• Timeliness: Form filed 2026-04-01 for a 2026-03-30 grant; this appears to be a timely Form 4 filing (insiders must generally file within two business days).

Context

• RSUs are a form of compensation that represents the right to receive shares (typically subject to tax when they vest). Because these were granted and vested immediately, this is a compensation/award event rather than a market purchase or sale and does not directly signal insider buying or selling activity.